Sign in
Taking people in United StatesPhase 2

Nicotine Regulation for Dual Users of E-cigarettes and Cigarettes

Key facts

Who runs it
University of Vermont
Where
Burlington and Providence, United StatesSee the 2 sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
308 people, planned
Started
1 Nov 2024
Expected to end
30 Sept 2028
Type of study
Interventional, 4 groups
Treatments tested
  • Varying the nicotine content of cigarettes
  • Varying the nicotine content of e-cigarettes
Record updated
27 June 2025

Who can take part

Age
21 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Regular use of tobacco
  • 21 year of age or older
  • Speak, comprehend and read English well enough to complete study procedures

Who cannot take part

  • Health conditions that could undermine ability to complete the study
  • Under the age of 21
  • Pregnant, trying to become pregnant, or nursing

This trial is currently available in United States.

  • University of VermontBurlington, United StatesContact: Emily BoothTaking people
  • Brown UniversityProvidence, United StatesContact: Kim DuguayTaking people

About the trial

What the trial wants to find out

Cigarette smoking remains the leading cause of preventable morbidity and mortality in the US. Use of multiple tobacco products is becoming increasingly prevalent, with dual use of e-cigarettes and cigarettes representing the most common combination. Though e-cigarettes are not without risk, completely switching from cigarettes to e-cigarettes likely reduces risk for tobacco-related harm. However, many established dual users maintain long-term smoking and the majority who use e-cigarettes non-daily are at an even greater risk for prolonged smoking than exclusive cigarette smokers. The Food and Drug Administration Center for Tobacco Products (FDA CTP) has announced plans to implement a nicotine-limiting product standard, capping the nicotine in cigarettes at a minimally or non-addictive level. Randomized controlled trials (RCTs) demonstrate that adults who exclusively smoke cigarettes respond to very low nicotine content (VLNC) cigarettes with reductions in smoking, demand, and dependence. However, nicotine reduction RCTs to date have excluded people who regularly use e-cigarettes and therefore it remains unclear how a nicotine-limiting standard for cigarettes would affect smoking among dual users. Given the potential substitutability of e-cigarettes for cigarettes, reducing the nicotine in cigarettes could promote a transition to exclusive e-cigarette use among dual users unable to completely quit nicotine, but only if sufficiently appealing e-cigarettes remain available. E-cigarettes containing 5% nicotine-salt solution are currently most popular in the US, but policy makers have proposed restricting e-cigarettes to ≤ 2% nicotine to curb youth e-cigarette use, and several states have already set limits to reduce nicotine in e-cigarettes. Prior laboratory studies indicate that higher vs lower nicotine e-cigarettes serve as better substitutes for cigarettes among adult dual users. As such, a restriction on e-cigarette nicotine concentration could undermine the potential for e-cigarettes to substitute for cigarettes and diminish the benefits of a nicotine-limiting standard for cigarettes among dual users. This study is a 12-week double-blind 2 cigarette level (Normal Nicotine vs Very Low Nicotine) x 2 e-cigarette level (High Nicotine vs Low Nicotine) between-subjects factorial trial to investigate how a nicotine-limiting standard for cigarettes affects adult dual users and whether these effects are impacted by constraints on e-cigarette nicotine concentration. Outcome measures include cigarettes per day, cigarette dependence, and toxicant exposure. The research is highly relevant to FDA CTP domains of Addiction and Behavior because it will test whether reducing the nicotine content of cigarettes reduces smoking and dependence, and whether these effects are moderated by the availability of high vs low nicotine e-cigarettes.

The 4 groups in the trial

  • RC 1 + REC 1Treatment being tested

    Research cigarettes #1 plus research e-cigarettes #1

    Treatment: Varying the nicotine content of cigarettes and Varying the nicotine content of e-cigarettes

  • RC 1 + REC 2Treatment being tested

    Research cigarettes #1 plus research e-cigarettes #2

    Treatment: Varying the nicotine content of cigarettes and Varying the nicotine content of e-cigarettes

  • RC 2 + REC 1Treatment being tested

    Research cigarettes #2 plus research cigarettes #1

    Treatment: Varying the nicotine content of cigarettes and Varying the nicotine content of e-cigarettes

  • RC 2 + REC 2Treatment being tested

    Research cigarettes #2 + research e-cigarettes #2

    Treatment: Varying the nicotine content of cigarettes and Varying the nicotine content of e-cigarettes

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized Controlled Trial of Reduced Nicotine Cigarettes and E-cigarettes Among Dual Users
Record updated
27 June 2025